

bibliographie

1. 2003 European Society of Hypertension. European Society of Cardiology. guidelines for the management of arterial hypertension. *J Hypertens* 2003 ; 21 : 1011-53.
2. Adler AI, Stratton IM, Neil HAW *et al.* UKPDS 35. Association of systolic blood pressure with cardiovascular and microvascular complications of type 2 diabetes : prospective observational study. *BMJ*, 2000, 321 : 412-419.
3. Afssa. Rapport sel : évaluation et recommandations Afssa Maisons Alfort, 2002.
4. Afssaps. La prise en charge thérapeutique du patient dyslipidémique. Argumentaire référence Agence française sécurité sanitaire des produits de santé 2000.
5. American College of Sports Medicine position stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness in healthy adults. *Med Sci Sports Exerc* 1990 ; 22 : 265-274.
6. Anaes. Prise en charge des patients adultes atteints d'hypertension artérielle essentielle, Recommandations cliniques et données économiques. Avril 2000.
7. Andem. Recommandations et références médicales- Hypolipidémiants. *Concours Médical* 1996 ; Suppl. au N°41 ; 7 déc. : 1-6.
8. Arwidson P, Léon C, Wilquin JL, Guilbert. Évolutions récentes de la consommation de tabac en France. *BEH*. 27 mai 2004.
9. Bertrais S, Preziosi P, Mennen L, Galan P, Hercberg S, Oppert JM. Sociodemographic and geographic correlates of meeting current recommendations for physical activity in middle-aged adults (the Su.Vi. Max study). *Am J Public Health* 2004 ; 94 : 1560-1566.
10. Boersma H *et al.* Cardiovascular diseases in Europe. Sophia Antipolis France European Society of Cardiology, 1999.
11. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. *N Engl J Med*. 2004 Apr 8;350(15):1505-15.
12. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. *Atherosclerosis*. 2003 Nov;171(1):1-13.
13. Chiasson JL, Josse RG, Gomis R *et al.* Acarbose et risques d'événements cardiovasculaires et d'hypertension artérielle chez les patients intolérants au glucose (IGT). Etude STOP-NIDDM. *JAMA*, 2003, 290 : 486-494.
14. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. *Hypertension*. 2000 ;35:858-863.
15. Coutinho M, Gerstein H, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A meta regression analysis of published data from 20 studies of 95,783 individuals followed for 12,4 years. *Diabetes Care*, 1999, 22 : 233-240.
16. D'Agostino RB, Russell MW, Huse DM *et al.* Primary and subsequent coronary risk appraisal: new results from the Framingham study. *Am Heart J* 2000 ; 139 : 272-81.
17. Dautzenberg B. Le tabagisme passif. La Documentation française. Paris, 2001.
18. Dawber TR, Kannel W, Revotskie N *et al.* The epidemiology of coronary heart disease. The Framingham Enquiry. *Proc Royal Soc Med* 1962;55:265-71.
19. Ducimetière P. La fréquence des maladies cardio-vasculaires en France et le « Paradoxe français ». *Méd Sciences* 2003;28:18-22.
20. Euroaspire I and II Group ; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. *Lancet*. 2001 31;357:995-1001.
21. Ezetrol 10 mg Avis de la commission 26 novembre 2003 Commission de la Transparence Afssaps.
22. Frérot L, Le Fur Ph, Le Pape A, Sermet C. L'hypertension artérielle en France : prévalence et prise en charge thérapeutique. *Biblio CREDES* N° 1276, septembre 1999.
23. Goede P, Vedel P, Larsen N *et al.* Multifactorial Intervention and Cardiovascular Disease in Patients with type 2 Diabetes. *N Engl J Med*, 2003, 348 : 383-393.
24. Gresser U, Gathof BS. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. *Eur J Med Res*. 2004 Jan 26;9(1):1-17.
25. Haut Comité de la santé publique. Pour une politique nutritionnelle de santé publique en France. Enjeux et propositions. Rennes, Editions ENSP, 2000.
26. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. *Hypertension*. 2000;35:544-549.
27. Hill C, Laplanche A. Tabagisme et mortalité : aspects épidémiologiques. *Bulletin épidémiologique hebdomadaire*. InVS, 27 mai 2003.
28. Inpes. La santé vient en mangeant : le guide alimentaire pour tous. Inpes, Saint Denis, 2002.
29. Inserm, OFDT. Premiers résultats de l'enquête ESPAD 2003 en France. Consommations de substances psychoactives des élèves de 12 à 18 ans : évolutions entre 1993 et 2003. Paris, 14 avril 2004.
30. Isomaa B, Almgren P, Tuoni T *et al.* Cardiovascular Morbidity and Mortality Associated with the Metabolic Syndrom. *Diabetes Care*, 2001 ; 24 : 683.
31. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A ; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*. 2004;363:2022-31.
32. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure. *Hypertension*. 2000 ; 35:838-843.
33. Kesaniemi YK, Danforth E Jr, Jensen MD, Kopelman PG, Lefebvre P, Reeder BA. Dose-response issues concerning physical activity and health: an evidence-based symposium. *Med Sci Sports Exerc* 2001 ; 33(6 Suppl) : S351-S358.
34. Le Fur Ph, Paris V, Pereira C, Renaud Th, Sermet C. Les dépenses de prévention dans les comptes nationaux de la santé : une approche exploratoire. *Credes, QES* n° 68, 7/2003.



bibliographie (suite)

35. Les registres français des cardiopathies ischémiques. L'infarctus du myocarde en France. Données des trois registres des cardiopathies ischémiques de Lille, Strasbourg et Toulouse. Période 1985-1992. Paris : Fédération française de cardiologie Éd. 1996.
36. Marques-Vidal P, Montaye M., Ruidavets JB., Amouyel Ph., Ferrières J. Evolution and cost trends of antihypertensive and hypolipidaemic drug treatment in France. *in Cardiovascular Drug and Therapy* 17 : 175-189 2003.
37. Manson JE, Hu FB, Rich-Edwards JW, Colditz GA, Stampfer MJ, Willett WC, Speizer FE, Hennekens CH. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. *N Engl J Med* 1999 ; 341 : 650-658.
38. Ménard J : Hypertension artérielle, contribution au groupe technique national de définition des objectifs préparatoires au projet de loi relatif à la politique de santé publique (GTND0). Mars 2003.
39. Ministère de la Santé. Direction générale de la Santé. Programme national de réduction des risques cardio-vasculaires 2002-2005. Février 2002.
40. Ministère de la Santé. Direction générale de la Santé. Programme national nutrition santé (PNNS) 2001-2005. Janvier 2001.
41. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial. *Lancet*, 2003, 361 : 2005-2016.
42. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs. *Lancet*. 2000;356:1955-1964.
43. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. *Hypertension*. 2000;35:539-543.
44. Paris V, Renaud Th, Sermet C. Décompte de la santé par pathologie : un prototype pour l'année 1998. Commission des comptes de la santé, 5 septembre 2002.
45. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, *et al*. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. *JAMA* 1995 ; 273 : 402-407.
46. Saba G, Weill A, Païta M, Ricordeau Ph, Bourrel R, Nouailher-Lagarde M, Dematons MN, Crochet B, Guilhot J, Fender P, Allemand H et le groupe Dyslipidémie. Instauration des traitements médicamenteux hypolipémiants en France en 2002. *In Revue Médicale de l'Assurance maladie* volume 34 n° 4/octobre-décembre 2003.
47. Sacks FM, Svetkey LP, Vollmer WM, *et al.*, for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *N Engl J Med*. 2001 ;344:3-10.
48. Sargent *et al*. Reduced incidence of admissions for myocardial infarction associated with public smoking ban : before and after.
49. Stratton IM, Adler AI, Neil HAW *et al*. UKPDS 35. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes : prospective observational study. *BMJ*, 2000, 321 : 405-412.
50. The lipid research clinics coronary primary prevention trial results. Reduction of the incidence of coronary heart disease. *JAMA* 1984 ; 251:351-364 questran LRC-CPPT Lipid Research Clinics Coronary Primary Prevention Trial.
51. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. *Arch Intern Med*. 1997;157: 657-667.
52. The Who Monica Project. A worldwide monitoring system for cardiovascular diseases : cardiovascular mortality and risk factors in selected communities. *World Health Stat Annu* 1989;27:149-62.
53. Tunstall-Pedoe H *et al*. Contribution of trends in survival and coronary event rates to changes in coronary heart disease mortality : 10-year results from 37 Who Monica Project populations. *Lancet* 1999;353:1547-57.
54. Turnbull F ; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003 ; 8;362:1527-35.
55. US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA : U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996. www.healthfinder.gov
56. UKPDS Study Group. UKPDS 33. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. *Lancet*, 1998 ; 352 : 837-853.
57. UKPDS Study Group. UKPDS 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. *BMJ*, 1998 ; 317 : 703-713.
58. Vaz de Almeida MD, Graca P, Afonso C, D'Amicis A, Lappalainen R, Damkjaer S. Physical activity levels and body weight in a nationally representative sample in the European Union. *Public Health Nutr* 1999 ; 2 : 105-113.
59. Vollmer WM, Sacks FM, Ard J, *et al*. Effects of diet and sodium intake on blood pressure. *Ann Intern Med*. 2001;135:1019-1028.
60. Wagner A, Simon C, Evans A, Ferrieres J, Montaye M, Ducimetiere P, Arveiler D. Physical activity and coronary event incidence in Northern Ireland and France: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). *Circulation* 2002 ; 105 : 2247-2252.
61. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure. *Ann Intern Med*. 2002 ; 136:493-503.
62. World health organization, International Society of Hypertension. 1999 World Health Organisation, International Society of Hypertension guidelines for the management of hypertension. *J Hypertension* 1999;17:151-83.
63. Xin X, He J, Frontini MG, *et al*. Effects of alcohol reduction on blood pressure. *Hypertension*. 2001;38: 1112-1117.